Tagged with R

Korea Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides her assessment of the impact of the merger. She also comments on Syneos Health’s MoU with KoNECT (Korea National Enterprise…

France Arnaud Gobet, president of Innothera, discusses how the company balances its unique and diverse offering of medical devices, hygiene and protection products and pharmaceuticals, Innothera’s burgeoning international footprint and the condition of France’s industrial environment.   In the long term, we see the suppression of the ISF (solidarity tax on…

Korea SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview, Jeong Woo Cho PhD, CEO & president of SK Biopharmaceuticals and SK Life Science, provides an overview of the current…

France Josephine Yang Comiskey, president of GSK France, gives insights into GSK’s corporate culture, portfolio and priorities in France. She also highlights the need for collaboration and a better dialogue between industry and authorities, to ensure quicker market access for innovative products in the country.   We welcome the fact that…

Korea Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains his strategy to expand into the East Asian market and provides his assessment on how established Korean pharmaceutical companies can…

USA 80 orphan drugs (those drugs intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions) were approved in the USA in 2017, a record year and more than double the 40 approved in 2016.   Orphan drug spending grew from 5 to 10%…

France Pierre Banzet, CEO of French CDMO Groupe SYNERLAB, shares how the group has developed over the past three years and discloses his strategy for generating specialty production knowledge as well as expanding the company’s footprint within Europe. Banzet also offers his assessment of key CDMO trends and the current condition…

Korea Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools, Bioneer’s globally distributed platform of molecular diagnostics, and its novel next-generation RNAi therapeutics platform SAMiRNA TM. Dr Park also comments…

France On February 4 in Paris, Minister of Health and Solidarity Agnès Buzyn, Minister of Higher Education, Research and Innovation Frédérique Vidal, Secretary of State to the Minister of Economy and Finance Agnès Pannier-Runacher, and President of the Healthcare Industry Strategic Committee (CSF) and Chairman of the French Federation of Health…

China Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved context in terms of drug regulation, ease of doing business, research capabilities and access to capital. Below, we highlight 5…

Malaysia The growth of the Malaysian pharma market between 2006 and 2016. Pharmaceutical sales grew to over USD 2 billion by 2016, thanks in large part to a burgeoning prescription medicine segment.   The import and export of pharmaeuticals in Malaysia between 2006 and 2016. In 2016, the trade balance stood…

France Stéphane Mathieu CEO for SIGVARIS GROUP’s Europe, South & West operations, discusses taking on a unique challenge as the company pivots towards becoming a fully-fledged health technology provider, and what ‘patient-centricity’ means to him.   The onus is firmly upon medtech players to become much more “patient-centric” in both their…